Yang Liu, PhD
Assistant Professor of PathologyCards
Appointments
Contact Info
About
Copy Link
Titles
Assistant Professor of Pathology
Biography
Yang Liu, PhD, was appointed Assistant Professor in the Department of Pathology effective August 1, 2022. Dr. Liu received his PhD degree from the University of California Riverside, working in quite a few different fields, including engineering, chemistry, toxicology, and computer science. He has been a Postdoctoral Research Associate at Yale since 2018 working with Dr. Rong Fan in the Department of Biomedical Engineering at Yale. During the Postdoc training, he developed a high spatial resolution multi-omics sequencing technique, named DBiT-seq, which can achieve near single-cell spatial resolution (10 µm) sequencing of RNA and protein on the same tissue section. He also developed Spatial-CITE-seq (High plex spatial epitome sequencing) and DBiT-seq FFPE technology (spatial transcriptome and epitome of banked FFPE samples). Dr. Liu received the SITC-SU2C Convergence Scholar Awards in 2019 and NIH Hubmap Jumpstart award. His Lab in Yale Pathology will focus on development of spatial based omics techniques (Transcriptome, proteome, epigenome, etc..) and the application of spatial omics techniques to study tumor microenvironments, neurological disease, heart and vascular disease, development and microbiome.
Appointments
Pathology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- PhD
- University of California, Riverside, Environmental Toxicology (2017)
- MS
- University of California, Riverside, Computer Science (2017)
- MS
- Chinese Academy of Science, Analytical Chemistry (2011)
- BS
- Huazhong University of Science & Technology, Computer Science (2008)
- BE
- Huazhong University of Science & Technology, Environmental Engineering (2008)
Research
Copy Link
Overview
Yang Liu, PhD, was appointed Assistant Professor in the Department of Pathology effective August 1, 2022. Dr. Yang Liu received his PhD degree from the University of California Riverside, working in quite a few different fields, including engineering, chemistry, toxicology, and computer science. He has been a Postdoctoral Research Associate at Yale since 2018 working with Dr. Rong Fan in the Department of Biomedical Engineering at Yale. During the Postdoc training, he developed a high spatial resolution multi-omics sequencing technique, named DBiT-seq, which can achieve near single-cell spatial resolution (10 µm) sequencing of RNA and protein on the same tissue section. He also developed Spatial-CITE-seq (High plex spatial epitome sequencing) and DBiT-seq FFPE technology (spatial transcriptome and epitome of banked FFPE samples). Dr. Liu received the SITC-SU2C Convergence Scholar Awards in 2019 and NIH Hubmap Jumpstart award. His Lab in Yale Pathology will focus on development of spatial based omics techniques (Transcriptome, proteome, epigenome, etc..) and the application of spatial omics techniques to study tumor microenvironments, neurological disease, heart and vascular disease, development and microbiome.
ORCIDs
- View Lab Website
Yang Liu Lab
Research at a Glance
Yale Co-Authors
Publications Timeline
Rong Fan, PhD
Mina Xu, MD
Joseph Craft, MD
David A. Hafler, MD, FANA, MSc
Stephanie Halene, MD, Dr Med
Ana Lledo Delgado, MD
Publications
2026
Updated efficacy results from the phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Wise D, Zhang T, Saraiya B, Avitia J, Armstrong A, Gulati S, Bupathi M, Sokolova A, Tutrone R, Shpyro S, Blokhina O, Wang Q, Liu Y, Durbin J, Zheng P, Stein M. Updated efficacy results from the phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2026, 44: 175-175. DOI: 10.1200/jco.2026.44.7_suppl.175.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerProgression-free survivalMedian follow-up timePhase 1 studyFollow-up timeRadiographic PFSTumor microenvironmentOverall survivalPre-treated metastatic castration-resistant prostate cancerMedian PSA progression-free survivalMedian radiographic progression-free survivalLu-177Androgen receptor pathway inhibitorsAnti-CTLA-4 antibodyPSA progression-free survivalRadiographic progression-free survivalCastration-resistant prostate cancerMedian PSA-PFSMedian radiographic PFSPhase 1/2 trialRegulatory T cellsPhase 1 trialPSA-PFSPSA50 rateTreg depletionSpecific depletion of TIGIThigh CD226− clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting
Zhou H, Li J, Mei S, Zhang M, Zhao H, Yan K, Cheng Y, Zhou Q, Zheng P, Liu Y, Zhang P, Li H, Lu W, Zhang Y. Specific depletion of TIGIThigh CD226− clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. Journal For ImmunoTherapy Of Cancer 2026, 14: e013636. PMID: 41735000, PMCID: PMC12933768, DOI: 10.1136/jitc-2025-013636.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsCD4+ T cellsAntibody-dependent cellular cytotoxicityIntratumoral TregsT cellsTumor-infiltrating CD8+ T cellsTherapeutic efficacyIntratumoral regulatory T cellsCD8+ T cellsNon-small cell lung cancerAntibody-dependent cellular cytotoxicity activitySingle-cell TCR sequencingFlow cytometryT helper cell 1Antitumor activityAnti-TIGIT antibodiesPoor immunotherapy responseTumor-infiltrating lymphocytesRegulatory T cellsEffector cell functionCell lung cancerTumor microenvironment alterationsKnock-In MiceCD226 expressionTIGIT blockadeTreg subsetsAnti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes
Wu Y, Spurrell M, Lledó-Delgado A, Deng S, Wang D, Liu Y, Barkestani M, Perdigoto A, Herold K. Anti-CD3 mAb treatment reshapes infiltrating T and β cells in the islets in autoimmune diabetes. JCI Insight 2026, 11: e192755. PMID: 41574610, PMCID: PMC12892913, DOI: 10.1172/jci.insight.192755.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAnti-CD3 mAb treatmentT cellsMAb treatmentAutoimmune diabetesB cellsCD8+ T cellsIslet-infiltrating T cellsAnti-CD3 monoclonal antibodyT-cell receptor sequencingPrediabetic NOD miceAutoreactive T cellsPancreatic lymph nodesImmune-mediated destructionCourse of treatmentType 1 diabetesInfiltrating TSingle-cell RNAIslet infiltrationMAb-treatedNOD miceLymph nodesEffector functionsOperational toleranceMonoclonal antibodiesProlonged effect
2025
Therapeutic activities of anti‐human SIGLEC10 mAb in Multiple Transgenic Mouse AD Models
Wang P, Esworthy T, Weiss I, Zheng P, Liu Y. Therapeutic activities of anti‐human SIGLEC10 mAb in Multiple Transgenic Mouse AD Models. Alzheimer's & Dementia 2025, 21: e101818. PMCID: PMC12739717, DOI: 10.1002/alz70859_101818.Peer-Reviewed Original ResearchConceptsAssociated with Alzheimer's diseaseMechanism of actionTherapeutic activityMouse modelMicroglia functionAD mouse modelBlood-brain barrierAD pathogenesisAD modelAmyloid plaquesImmunotherapy agentsIn vitro phagocytosisMouse primary microgliaClinical benefitComparison to controlsTransgenic mouse AD modelClinical developmentIn vitro phagocytosis assayTransgenic miceAD pathogenic processFlow cytometryBrain barrierMonoclonal antibodiesMicePrimary microgliaMice Carrying Unmutated Human SIGLEC10 Gene Cluster Transgene Develop Both Amyloid Plaques and Tau Neurofilament Tangles: A Model for Late Onset Alzheimer’s Disease
Wang P, Weiss I, Zheng P, Liu Y. Mice Carrying Unmutated Human SIGLEC10 Gene Cluster Transgene Develop Both Amyloid Plaques and Tau Neurofilament Tangles: A Model for Late Onset Alzheimer’s Disease. Alzheimer's & Dementia 2025, 21: e101773. PMCID: PMC12740684, DOI: 10.1002/alz70859_101773.Peer-Reviewed Original ResearchConceptsLate-onset Alzheimer's diseaseGenome-wide association studiesGene clusterAD pathogenesisAlzheimer's diseaseHuman gene clustersPTau aggregationAssociated with pathogenic mutationsPathogenesis of late-onset ADTargeted deletionHuman genomic fragmentLate-onset ADEarly onset ADSiglec genesGenomic fragmentsAssociation studiesAD brainAD hallmarksAD tauopathyAmyloid plaquesPathogenic mutationsTransgenic miceProtein aggregationExclusive expressionTransgenic developmentSpatial dynamics of brain development and neuroinflammation
Zhang D, Rubio Rodríguez-Kirby L, Lin Y, Wang W, Song M, Wang L, Wang L, Kanatani S, Jimenez-Beristain T, Dang Y, Zhong M, Kukanja P, Bao S, Wang S, Chen X, Gao F, Wang D, Xu H, Ma C, Lou X, Liu Y, Chen J, Sestan N, Uhlén P, Kriegstein A, Zhao H, Castelo-Branco G, Fan R. Spatial dynamics of brain development and neuroinflammation. Nature 2025, 647: 213-227. PMID: 41193846, PMCID: PMC12589135, DOI: 10.1038/s41586-025-09663-y.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBrain developmentPostnatal day 0Chromatin accessibilitySpatial dynamicsTranscription factorsOmics informationMyelin genesDevelopmental processesProjection neuronsNeuroinflammation mouse modelMolecular programsMouse modelDisease-related alterationsTransient activationLesion coreCorpus callosumMultiplexed immunofluorescence imagesSequenceDevelopmental timepointsSpatial remodelingDay 0Mouse brainDynamics of brain developmentImmunofluorescence imagingNeuroinflammationP3.18.39 PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 Inhibitors
Li T, Wu Y, Cho B, Balaraman R, Chen H, Fawole A, Yu X, Liu Z, Zhang J, Hamm J, Long W, Yang B, Leddon J, Huang Y, Pan P, Shpyro S, Wang Q, Zheng P, Liu Y, Efuni S, He K, Socinski M. P3.18.39 PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 Inhibitors. Journal Of Thoracic Oncology 2025, 20: s562. DOI: 10.1016/j.jtho.2025.09.1054.Peer-Reviewed Original ResearchEpigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC Profiling.
Wang D, Di X, Gao F, Li G, Lin L, He S, Zhang D, Jin JY, Liang Y, Cecchini M, Lacy J, Kunstman J, Kunz P, Du J, Liu Y. Epigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC Profiling. BioRxiv 2025 PMID: 41000913, DOI: 10.1101/2025.09.11.675640.Peer-Reviewed Original ResearchCD24-Fc resolves inflammation and enhances anti-HIV CD8 T cells with polyfunctionality during HIV-1 infection under cART
Li G, Ma J, Yu H, Tsahouridis O, Lou Y, He X, Funaki M, Zheng P, Liu Y, Su L. CD24-Fc resolves inflammation and enhances anti-HIV CD8 T cells with polyfunctionality during HIV-1 infection under cART. PLOS Pathogens 2025, 21: e1012826. PMID: 40779581, PMCID: PMC12349878, DOI: 10.1371/journal.ppat.1012826.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPeripheral blood mononuclear cellsHIV-1 infectionCentral memory T cellsMemory T cellsT cellsHIV-1Humanized miceDanger-associated molecular patternsCD8 central memory T cellsPersistence of HIV-1 reservoirsRecovery of CD4 T cellsRisk of non-AIDS eventsChronic inflammationChronic HIV-1 infectionImmune hyper-activationHIV-1 reservoirNon-AIDS eventsHIV-1 pathogenesisCD8 T cellsSystemic immune activationAssociated with chronic inflammationCD4 T cellsAnti-retroviral therapyT cell activationBlood mononuclear cellsPhase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Wise D, Zhang T, Tutrone R, Saraiya B, Armstrong A, Sokolova A, Gulati S, Avitia J, Bupathi M, Shpyro S, Wang Q, Liu Y, Zheng P, Stein M. Phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2025, 43: 5067-5067. DOI: 10.1200/jco.2025.43.16_suppl.5067.Peer-Reviewed Original ResearchCitationsConceptsMetastatic castration-resistant prostate cancerDose-escalation phaseTumor microenvironmentCombination regimensEscalation phaseLu-177Androgen receptor pathway inhibitionCastration-resistant prostate cancerPhysician's choiceEfficacy-evaluable populationDepletion of TregsDose-limiting toxicityInfusion-related reactionsMedian Follow-UpRegulatory T cellsPhase 1 studyDose-optimization studyPSA50 rateDose escalationOS improvementOpen-labelTreatment discontinuationDosing regimensMedian ageProstate cancer
Academic Achievements & Community Involvement
Copy Link
Honors
honor The HuBMAP Jump Start Award
08/01/2021National AwardNIHDetailsUnited Stateshonor SITC-SU2C Convergence Scholar Awards
09/01/2019National AwardSITC-SU2CDetailsUnited States
News
Copy Link
Get In Touch
Copy Link
Contacts
Locations
Office
Academic Office
300 George Street
New Haven, CT 06511
Lab
Lab
300 George Street
New Haven, CT 06511